NCT02214381View on ClinicalTrials.gov

A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

January 15, 2025

Conditions

Early Primary Breast Cancer

Interventions

DRUG

Myocet

DRUG

Cyclophosphamide

DRUG

Paclitaxel

Trial Locations (2)

41061

Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, Mönchengladbach

81337

Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern, Munich

All Listed Sponsors

collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

West German Study Group

OTHER

NCT02214381 - A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response | Biotech Hunter | Biotech Hunter